The Spanish pharmaceutical manufacturer Grifols announced on Tuesday that it had approved the initial public offering of its biopharmaceutical business in the United States.
Grifols, which produces medications from blood plasma, plans to go public with a minority stake in the biopharmaceutical business. The parent company will remain listed on the stock exchange in Spain and retain the majority of the shares in the American business.
“The transaction strengthens Grifols’ self-sufficiency vision by creating the first and only player that will not rely on plasma, manufacturing, or sourcing outside the United States,” Grifols stated.
Selling the stake through an IPO would raise capital to bolster the balance sheet, reduce debt, and support investments in key markets, the company added.
Grifols stated in February that it expects core earnings to increase by more than a quarter in 2026 and will continue to reduce its debt, after declaring a profit in 2025 that more than doubled.
The group will further develop its plasma and diagnostics activities in other key markets, it announced on Tuesday.
